Manufacturing News of Note—AveXis goes deeper on Zolgensma manufacturing; 76B opioid pills manufactured

stocks
According to a new report, the active pharmaceutical ingredient market is projected to reach $213.84 billion in 2021, up from $148.22 billion in 2015. (Pixabay)

Here is some news of note for the week: 

> Catalent Biologics and Novartis’ company AveXis have struck a long-term deal in which the biotech will have dedicated manufacturing space at a Catalent facility for the production of AveXis' Zolgensma, its newly approved gene therapy for spinal muscular atrophy. Release 

> Data recently released as part of a civil action show that U.S. drugmakers manufactured 76 billion oxycodone and hydrocodone pills from 2006 through 2012 as the opioid epidemic spread. Story

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

> According to a new report, the active pharmaceutical ingredient market is projected to reach $213.84 billion in 2021, up from $148.22 billion in 2015. Release

 


 

Suggested Articles

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.